

Table 6. Pulmonary Toxicity Associated with Biologic Response Modifiers

Biologic Response Modifier	Clinical syndromes	Potential risk factors
Epidermal growth factor receptor tyrosine kinase inhibitors	<ul style="list-style-type: none"> • Interstitial pneumonitis 	<ul style="list-style-type: none"> • pre-existing interstitial lung disease • concurrent cardiac disease • older age • poor performance status, • smoking
All-trans retinoic acid	<ul style="list-style-type: none"> • Retinoic acid syndrome 	
Vascular endothelial growth factor inhibitors	<ul style="list-style-type: none"> • Hemoptysis, pulmonary hemorrhage 	<ul style="list-style-type: none"> • Pre-existing hemoptysis • Squamous cell lung cancer histology
Rituximab	<ul style="list-style-type: none"> • Infusion reaction • Interstitial pneumonitis 	
Interleukin-2	<ul style="list-style-type: none"> • Noncardiogenic pulmonary edema, hemodynamic instability, renal insufficiency, cardiac arrhythmias 	